Basel, Switzerland, April 19, 2023. Engimmune Therapeutics AG (“Engimmune”), a Swiss biotech company developing novel T-cell receptor (TCR)-based therapeutics, today announces the appointment of Dr. Lars Nieba as Chief Executive Officer. Dr. Søren Mouritsen, co-founder and previous CEO, steps down in a planned transition. Dr. Lars Nieba brings more than 25 years of experience in […]
Cambridge, UK, 28 July 2022, – NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces that it has entered a three-year research collaboration agreement with Memorial Sloan Kettering Cancer Center (MSK) in New York, USA. The objective of the collaboration is to determine the potential of NeoPhore’s proprietary DNA mismatch repair inhibitor (MMRi) compounds to enhance […]
eTheRNA immunotherapies NV (‘eTheRNA’), a private clinical-stage biotechnology company developing mRNA-based immunotherapies for the treatment of cancer and infectious diseases, will be attending the following conferences from December 2021 to March 2022: BioFIT Digital 7-9 December 2021 Tim Van Assche, VP of Business Development and Alliance will be in attendance. ESMO Immuno-Oncology Online Congress 8-11 […]